Analyst firms · Citizens JMP · ACAD
Citizens JMP ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Citizens JMP rates ACADIA Pharmaceuticals Inc. (ACAD) Market Outperform with a $35 price target, as of its latest action on Mar 1, 2022. It has published 4 rating actions on ACAD since December 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Market Outperform
- Price target
- $35
- Median target, all firms
- $31
- Actions on ACAD
- 4
Citizens JMP price target on ACAD
Every Citizens JMP rating on ACAD
- Mar 1, 2022
- Dec 21, 2021
- Dec 9, 2021
- Dec 7, 2021
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Citizens JMP and ACAD
- What is Citizens JMP's price target for ACAD?
- Citizens JMP's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $35, from its action on Mar 1, 2022.
- What is Citizens JMP's rating on ACAD?
- Citizens JMP rates ACAD Market Outperform, a bullish rating, as of Mar 1, 2022.
- When did Citizens JMP last change its view on ACAD?
- On Mar 1, 2022, Citizens JMP cuts its price target to $35 from $42, keeps Market Outperform.
- How does Citizens JMP's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Citizens JMP ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.